Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Astex Therapeutics will work with Janssen Pharmaceutica, a Johnson & Johnson company in Belgium, to develop anticancer drugs. In exchange for $37 million in upfront fees, research funding, and an equity investment in Astex, Janssen gets an exclusive license to compounds from the British firm's fibroblast growth factor receptor (FGFR) inhibitor program. Astex has discovered selective FGFR inhibitors using its fragment-based drug discovery platform. Astex could receive $500 million or more, excluding royalties, in milestone payments.
This article has been sent to the following recipient: